Cargando…
LEAP2 deletion in mice enhances ghrelin's actions as an orexigen and growth hormone secretagogue
OBJECTIVE: The hormone liver-expressed antimicrobial peptide-2 (LEAP2) is a recently identified antagonist and an inverse agonist of the growth hormone secretagogue receptor (GHSR). GHSR's other well-known endogenous ligand, acyl-ghrelin, increases food intake, body weight, and GH secretion and...
Autores principales: | Shankar, Kripa, Metzger, Nathan P., Singh, Omprakash, Mani, Bharath K., Osborne-Lawrence, Sherri, Varshney, Salil, Gupta, Deepali, Ogden, Sean B., Takemi, Shota, Richard, Corine P., Nandy, Karabi, Liu, Chen, Zigman, Jeffrey M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452786/ https://www.ncbi.nlm.nih.gov/pubmed/34428557 http://dx.doi.org/10.1016/j.molmet.2021.101327 |
Ejemplares similares
-
Disrupting the ghrelin-growth hormone axis limits ghrelin's orexigenic but not glucoregulatory actions
por: Gupta, Deepali, et al.
Publicado: (2021) -
OR12-04 LEAP2 Deletion Does Not Counteract The Effects Of Ghrelin Deletion During Insulin-Induced-Hypoglycemia
por: Shankar, Kripa, et al.
Publicado: (2023) -
Ghrelin cell–expressed insulin receptors mediate meal- and obesity-induced declines in plasma ghrelin
por: Shankar, Kripa, et al.
Publicado: (2021) -
“A LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetes”
por: Gupta, Deepali, et al.
Publicado: (2020) -
Ghrelin does not impact the blunted counterregulatory response to recurrent hypoglycemia in mice
por: Shankar, Kripa, et al.
Publicado: (2023)